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due to the reduction of serum antibody titers gained from previous
immunizations.Children are at an high risk for developing hepatitis B virus
(HBV) infection from immunosuppression secondary to chemotherapy and
multiple blood transfusions. Most of the children infected with HBV
develop chronic hepatitis. An Indian study by Jacob Puliyel et al, showed at
6 years of age, protective levels of anti-HBs antibody (>10 mlU/mL) were
present only in about 59% of those immunized. By 11 years, only 13% had
protective levels. The increasing potential for the cure of childhood ALL
emphasizes the need for a method of reducing hepatitis and its sequelae in
these children. Our study revealed only 68.8% children with newly diag-
nosed ALL had protective antiHBstitres (>10IU/L), while 31.2% children had
no immunity tohepatitis B despite presumed vaccination as part of the UIP
schedule.
Conclusion: A signiﬁcant number of newly diagnosed children with ALL
lack protective anti HBs titres despite being vaccinated according to Uni-
versal Immunization Programme and Combined passive active immuni-
sation should be considered for them.
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Introduction: ETPALL is a recently well described high-risk subset of T-ALL
with early differentiation arrest and showing features overlappingwith AML
andwith poor prognosis which can potentially be improvedwith intensiﬁed
induction using dexamethasone and high-dose L-asparaginase. We audited
our experience with ETP-ALL for its clinical proﬁle and outcome.
Methods: We retrospectively evaluated all children (<15yrs) diagnosed
with ETP-ALL or Near ETP-ALL from January 2012 to December 2015. All
were treated with institutional ALL protocol (modiﬁed MCP-841) with
4drug induction incorporating prednisolone and high dose Ara-C in
consolidation (16g/m2). From June 2014, the protocol was amended by
substituting prednisolone with dexamethasone (10mg/m2/dy) in induc-
tion along with higher intensity of L-asparaginase (10000 U/m2/dose).
Results: T-ALL was diagnosed in 283 children, of whom 34 were ETP-ALL
(14%) and 5 were Near ETP-ALL (1.7%): Median age was -13 years; Male : fe-
male- 2.5:1; Bulky disease-18%; mediastinal mass-12.8%; median WBC
count- 10.1x109/mm3; Hyperleucocytosis (>100x109mm3)- 10%; No CNS
involvement.DemographicsofT-ALL insameperiod:medianage-9yrs;male:
Female 4:1; medianWBC count- 50x109 /mm3; hyperleucocytosis-36.7%.
Of 39 childrenwith ETP-ALL, 32 took treatment. At a median follow-up of 10
months (range3 -50months), the2-yearOS is52.5%andEFS is53.7%.Median
OS is not reached as yet. Of 32 patients, 15 received prednisolone based in-
duction and17 received dexamethasonebased intensive induction. Overall 8
(25%) died during induction therapy (dexamethasone arm e 29.4%, pred-
nisolone arm -20%). Of the evaluable 24 patients (dexamethasone arm-12,
prednisolone arm-12),18 patients (75%) achieved complete morphological
remission at the end of induction (dexamethasone arm-58%, prednisolone
arm-92%, p¼0.15). Of 14 patients whose Minimal Residual Disease (MRD)
datawere available (12 of whom received dexamethasone based induction),
5 patients were MRD negative post induction (35.7%), and corresponding
morphological remission was seen in 9 (50%). Of the 9 patients who were
MRD positive post induction,7 (78%) cleared MRD post subsequent cycles
.There has been no relapse so far and the projected 2-year DFS is 89%.
Conclusions: ETP-ALL constituted 16% of T-ALL children. Children with
ETP-ALL had higher median age, low disease burden at presentation and
infrequent CNS involvement. The disease free survival with this protocol
using high dose cytarabine based consolidation is good. However inten-
siﬁcation of therapy in induction did not improve remission rates but led to
higher induction mortality and poorer overall outcome in our low-middle
income setting.LM-1_V1.4
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Introduction: Acute lymphoblastic leukemia (ALL) is a hematologic ma-
lignancy that predominantly occurs in children between 2 and 10 years of
age. L-asparaginase is an integral component of treatment for patients
with ALL and since its introduction into pediatric treatment protocols in
the 1960s, survival rates in children have progressively risen to nearly 90%.
The effects of L-asparaginase on hemostasis during induction chemo-
therapy are less deﬁned in children. These hemostatic modiﬁcations
induced by L-asparaginase are relatively rare and mild in children, but
their incidence has not yet beenwell evaluated and their Toxicity proﬁle in
Indian children is very rarely documented.
Aims and Objectives: Primary Objective: To demonstrate the toxicity
proﬁle of L- Asparaginase in childrenwith Acute Lymphoblastic Leukaemia
speciﬁcally to evaluate hyperlipidemia and changes in coagulation and
thrombotic risk.
Secondary Objective: To study the differences in toxicities of L-Aspar-
aginase between the two types of L-Asparaginase (E coli and Pegylated).
Methodology:
 Children after the diagnosis with acute lymphoblastic leukemia under-
went baseline investigations with Liver function tests, Lipase, PT, PTT, INR,
Random blood sugar and Lipid proﬁle prior to the onset of treatment and
thereafter weekly during induction and re induction periods.
 Antithrombin III and ﬁbrinogen were done twice during induction (day
15 and 29) and once during reinduction therapy (on day 22).
 Demographic data, clinical details, details of diagnosis, Laboratory values
were recorded in a proforma. Analyzed data were analysed using SPSS 16.
The study was approved by our institution ethics committee.
 The study was funded by Tiara Hemophilia Cancer Foundation, NGO
supporting in Chennai supports pediatric cancer researches.
Results: 80 cases were included in this study of which 53 were males and
27 were females. Pre B cell leukemia were 57 and T cell Leukemia were 23.
Type of L- Asparagine used were E coli Asparaginase (n-50) and Pegylated
L Asparaginase (n-30). Complications seen were elevated lipase level
without any evidence of clinical pancreatitis 12.5%, Hyperglycemia 12.5%,
hyperlipidemia 10%, Thrombosis 2.5%, Allergies 5.6%, elevated PT/PTT 10%;
Low AT 3 (15.5%) and low ﬁbrinogen (16.5%).
There is no Statistical difference between the two groups of L-Asparginase
studied, however increase side effects were noted in Ecoli Asparaginase
group.
Conclusion:
 Asparaginase is a critical component of all pediatric ALL protocols, with
many protocols incorporating prolonged and high intensity L-Aspar-
aginase treatment, it is important that our Indian data be available of all
potential treatment-related toxicities.
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Introduction: Hyperglycemia occurs in about 10-16% of children during
induction chemotherapy for acute lymphoblastic leukemia (ALL), which
includes steroids and L asparaginase. Patients may present with diabetic
ketoacidosis or non-ketotic hyperglycemic hyperosmolar syndrome. Hy-
perglycemia has also been reported to suppress immune function by in-
hibition of endogenous production of interleukins 2, 6 and 10 and
uncontrolled diabetes is a risk factor for developing invasive fungal
infections.
Materials and Methods: This study analysed the incidence and outcome
of hyperglycemia in pediatric patients (0-14yrs) during induction
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our institute, from January 1st 2015 to December 31st 2015. Hyperglyce-
miawas diagnosed with a random blood sugar (RBS) level of200mg/dl or
a fasting blood sugar (FBS) value of 126mg/dl. Patients with pre-existing
diabetes were excluded from analysis.
Results: 165 children with newly diagnosed ALL were analysed of which
eight patients (4.8%) were detected to have hyperglycemia (Range 139 e
646mg/dl). Seven of the patients were females and 50% of them were 10
years of age. No patient had pre-existing diabetes. Five patients (62.5%)
required insulin along with metformin to attain adequate glucose control
while two patients were treated with metformin alone. One of the patients
developed hyperglycemia with an RBS of 264while on treatment for septic
shock and expired shortly after. One child presented with ketoacidosis
associated with blood sugar of 554mg/dl and also had pancreatitis. Two
children had a family history of diabetes mellitus.
Conclusion: The occurrence of hyperglycemia in our study was lower than
previously reported in literature. The incidence of hyperglycemia was
signiﬁcantly increased in female children  10 years of age (p¼0.002).LM-1_V1.6
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Introduction: Acute Lymphoblastic Leukemia is hallmarked by hetero-
geneous characteristics and treatment responsiveness in different sub-
types. Although, the overall cure rate of ALL has improved signiﬁcantly
over the past few decades, cure rates for speciﬁc ALL subgroups vary
signiﬁcantly. Age at diagnosis is identiﬁed as an important prognostic
marker of pediatric ALL. This study aims at analyzing clinical, hemato-
logical, biochemical, immunophenotypical parameters and treatment
responsiveness in children upto two years of age, who are diagnosed with
ALL.
Materials & methods: It is a retrospective data analysis conducted at a
Tertiary Care Cancer Centre in South India. The study population includes
all Pediatric ALL upto 2 years of age, registered at this institute during
January 2009 to December 2013. The details included in the study were
collected from case records, hospital cancer registry and during follow up
and percentages were calculated for the variables using appropriate sta-
tistical tools.
Results: The total number of pediatric malignancies registered during the
period were 2640, out of which 422 cases were under 2 years of age with
ALL contributing 122 cases (29%).Among them, 48 children refused treat-
ment due to various reasons and four were lost to follow up. Thus, 70
children are eligible for analysis.
Among 70 children, infants were 13 (18%) and the remaining 57 children
(82%) were in the 1-2 years group. There were 39 males (56%) and 31 fe-
males (44%), the ratio being 1.25:1. Fever was present in 62 children (88%),
and pallor in 57 (81%). Hepatosplenomegaly was observed in 59 children
(84%) and isolated hepatomegaly in 9 (14%). Lymphadenopathy was noted
in 52 (74%).Bleeding manifestations were present in 9 (11.5%) and paroti-
domegaly in 3 (4.25%).
Hemogram revealed hemoglobin <7gm/dL in 25 children (35%), 7-11 gm/
dL in 35 (50%) and >11 in 10 (15%).Initial WBC count was < 10,000 in 25
children (36%), another 36% had counts between 10,000- 49,000 and the
remaining 20 (28%) hadmore than 50000.Platelet count was <20,000 in 14
children (20%), 20,000-99,000 in 51 (74%) and >1 lakh in 6%.
Serum LDH was elevated (>250 IU) in 45 children (64%) and Uric acid in 8
(11.5%).Renomegaly was detected by ultrasound in 12 (17%).Only one child
had CNS 3 disease.L1morphologywas seen in 66 children (94%) and L2 in 4
(6%). Immunophenotype was done in 44 children, 41 (93%) were Precursor
B ALL and 3 (7%) Precursor T ALL.
Event Free Survival was 63%. Among 26 children who succumbed (37%),
three died before the commencement of chemotherapy (4.3%), 6 childrendied during induction (8.5%) and 17 (24.2%) died after relapse. Four out of
11 infants (36%) and 40 among 1-2 years group (70%) survived.
Conclusion: Commonest clinical features were fever, hepatosplenomegaly
and pallor. Predominant morphology was L1 and immunophenotype,
Precursor B ALL. Treatment of infantile ALL is a challenge and is associated
with signiﬁcantly lower survival as compared to 1-2 years group.
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Purpose: To evaluate treatment response, patterns of failure and prog-
nostic factors for patients with NLPHL treated at the Tata Memorial Hos-
pital (TMH).
Materials and Methods: Between January 2008 & July 2013, 62 patients
with histologically proven NLPHL in the age group of 6-70yrs (Median
30.6Yrs) were treated at TMH. Forty ﬁve (73%) were males. Majority had
Stage I (48%) & Stage II (24%) disease. Fifteen (24%) had bulky disease at
presentation. Sixteen (26%) were treated with Involved Field Radiation
Therapy (IFRT) alone, 18 (29%) received Chemotherapy (CTh) alone, while
23 (39%) received a combination of CTh followed by IFRT. Five patients
underwent surgery as the local treatment. The IFRT doses were in the
range of 20-36 Gy. Thirty-four (80%) patients received ABVD CTh. Five (8%)
patients received Rituximab. Primary MINE CTh was used for 4 (6%)
patients.
Results: After a median follow-up of 18 months, the 2 year disease free
survival (DFS) and overall survival (OS) were 86% and 98% respectively.
Complete response (CR) at completion of primary treatment was 94%. At
last follow up 55 (89%) were alive without disease. Two (3%) patients each
had in-ﬁeld, out of ﬁeld and disseminated relapse. Four (6%) had residual
disease and one (2%) had transformation to DLBCL. Six (55%) patients
received salvage treatment (3 IFRT, 3 CTh), of which 4 were disease free at
last FU. On univariate analysis, early stage, absence of B symptoms and use
of IFRT resulted in superior DFS. For patients with early stage disease (stage
I and II), there was no difference in DFS (94%) between patients receiving
IFRT alone and CTh + IFRT. The use of IFRT was associated with improved
DFS (91% vs. 78%, p¼0.57). All patients tolerated treatment well without
any grade III or IV toxicities.
Conclusion: NLPHL is associated with excellent overall survival. For pa-
tients with early stage disease, IFRT alone results in similar outcomes
compared to CTh+IFRT. Early Stage at presentation, absence of B symptoms
and the use of IFRT confers superior outcome.
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Introduction: Ph +ve ALL is a very high-risk subset of childhood ALL with
historically poor outcomes without stem cell transplantation (SCT) before
the advent and use of Imatinib Mesylate. The incidence of Ph +ve ALL at our
centre is higher at 7% as compared to 2-3% in the west. There is a paucity of
data on the clinical presentation outcomes of Ph+ve ALL in India, where
SCT is not affordable for most patients.
Aim: We conducted a retrospective analysis of paediatric Ph +ve ALL pa-
tients treated with intensive chemotherapy with or without Imatinib.
